Journal
Clinical Cancer Research
Publication Date
9-2-2025
Volume
31
Issue
17
First Page
3644
Last Page
3651
Document Type
Open Access Publication
DOI
10.1158/1078-0432.CCR-24-1821
Rights and Permissions
Grierson PM, Wolf C, Suresh R, Wang-Gillam A, Tan BR, Ratner L, Oppelt P, Aranha O, Frith A, Pedersen KS, Spann J, Boice N, Brown A, Baer JM, Butka EG, Ahmad F, Xu Y, Liu J, DeNardo DG, Lim KH. Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. Clin Cancer Res. 2025 Sep 2;31(17):3644-3651. doi: 10.1158/1078-0432.CCR-24-1821 This open access article is distributed under the Creative Commons AttributionNonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. ©2025 The Authors; Published by the American Association for Cancer Research
Recommended Citation
Grierson, Patrick M; Wolf, Crystal; Suresh, Rama; Wang-Gillam, Andrea; Tan, Benjamin R; Ratner, Lee; Oppelt, Peter; Aranha, Olivia; Frith, Ashley; Pedersen, Katrina S; Spann, Jennifer; Boice, Nicholas; Brown, Amberly; Baer, John M; Butka, Emily G; Ahmad, Faiz; Xu, Yifei; Liu, Jingxia; DeNardo, David G; and Lim, Kian-Huat, "Neoadjuvant BMS-813160, nivolumab, gemcitabine, and nab-paclitaxel for patients with pancreatic cancer." Clinical Cancer Research. 31, 17. 3644 - 3651. (2025).
https://digitalcommons.wustl.edu/oa_4/5293
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
